D
Do Young Kim
Researcher at Yonsei University
Publications - 737
Citations - 18320
Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
Joong-Won Park,Yoon Jun Kim,Do Young Kim,Si Hyun Bae,Si Hyun Bae,Seung Woon Paik,Youn Jae Lee,Hwi Young Kim,Han Chu Lee,S. Han,Jae Youn Cheong,Oh Sang Kwon,Jong Eun Yeon,Bohyun Kim,J.S. Hwang +14 more
TL;DR: For patients with advanced hepatocellular carcinoma requiring sorafenib therapy, co-administration with conventional transarterial chemoembolization did not improve overall survival compared to sorafanib alone, but sorAFenib combined with cTACE significantly improved time to progression, progression-free survival, and tumor response rate.
Journal ArticleDOI
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection
Young Joon Yoon,Hye Young Chang,Sang Hoon Ahn,Ja Kyung Kim,Yong Kwang Park,Dae Ryong Kang,Jun Yong Park,Sung Min Myoung,Do Young Kim,Chae Yoon Chon,Kwang Hyub Han +10 more
TL;DR: In this article, the authors evaluated the association of MDM2 and p53 polymorphisms with the presence and early onset of hepatocellular carcinoma (HCC) in Korean patients with chronic hepatitis B virus (HBV) infection.
Journal ArticleDOI
The properties of plasma-enhanced atomic layer deposition (ALD) ZnO thin films and comparison with thermal ALD
TL;DR: In this paper, a hexagonal wurzite phase with preferential orientation was obtained for both cases, and significant differences were observed in various aspects of film properties including resistivity values between these two techniques.
Journal ArticleDOI
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B†
Hyun Woong Lee,Hyun Woong Lee,Heon Ju Lee,Jae Seok Hwang,Joo Hyun Sohn,Jae Young Jang,Kijun Han,Jun Yong Park,Do Young Kim,Sang Hoon Ahn,Yong Han Paik,Chun Kyon Lee,Kwan Sik Lee,Chae Yoon Chon,Kwang Hyub Han +14 more
TL;DR: The lamivudine‐induced virologic response was durable in patients under 40 years old and those receiving lamivUDine for more than 12 months after HBeAg clearance or seroconversion, and age and additional treatment were major predictive factors for SVR.
Journal ArticleDOI
Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats
Yong Han Paik,Ja Kyung Kim,Jung Il Lee,Se Hun Kang,Do Young Kim,S. H. An,Se Joon Lee,Dong Ki Lee,Kwang Hyub Han,Chae Yoon Chon,Sang In Lee,Kwan Sik Lee,David A. Brenner +12 more
TL;DR: Celecoxib shows a proapoptotic effect on HSCs through Akt inactivation and shows antifibrogenic effects in BDL- and TAA-treated rats, suggesting celecoxib as a novel antifIBrotic agent of hepatic fibrosis.